A Promising Drug Target for Multiple Chronic Diseases: IGLV1-41 (Immunoglobulin Lambda Variable 1-41)

Target Name: IGLV1-41

NCBI ID: G28824

IGLV1-41

Other Name(s): Immunoglobulin lambda variable 1-41 (pseudogene) | V1-14P | immunoglobulin lambda variable 1-41 (pseudogene) | IGLV141

A Promising Drug Target for Multiple Chronic Diseases: IGLV1-41 (Immunoglobulin Lambda Variable 1-41)

Immunoglobulin lambda variable 1-41 (IGLV1-41), also known as human Immunoglobulin Lambda (HIL), is a 136-kDa protein that plays a crucial role in the development and maintenance of the immune system. It is a glycoprotein that is expressed in various tissues and cells of the body, including the spleen, thymus, peripheral blood, and various organs. IGLV1-41 has been implicated in the pathogenesis of numerous chronic diseases, including autoimmune disorders, cancer, and neurodegenerative diseases. As a result, targeting IGLV1-41 has become an attractive research focus in recent years.

Disease-Related IGLV1-41 Expression

IGLV1-41 is highly expressed in various diseases, including autoimmune disorders such as rheumatoid arthritis (RA), lupus, and multiple sclerosis. In these diseases, IGLV1-41 is often present in the peripheral tissues, including the spleen, lymph nodes, and blood. IGLV1-41 is also expressed in various organs, such as the lungs, liver, and kidneys. The high expression of IGLV1-41 in these diseases has been associated with the pathogenesis of these conditions, as it may contribute to the immune dysregulation that characterizes these diseases.

IGLV1-41 and Cancer

Cancer is another disease in which IGLV1-41 has been highly expressed. In various types of cancer, including breast, lung, and colorectal cancer, IGLV1-41 is often present in the tissues and cells of the affected organs. IGLV1-41 has also been shown to be involved in cancer progression and the development of cancer-initiating events. For example, studies have shown that IGLV1-41 can promote the growth and metastasis of various cancer cell types, and can also contribute to the development of cancer-associated autoantibodies.

Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. IGLV1-41 has been implicated in the pathogenesis of these diseases, as it has been shown to be involved in the development and progression of neurodegenerate diseases. For example, studies have shown that IGLV1-41 can contribute to the development of neurofibrillary tangles in the brain, and can also promote the growth of neurodegenerate cells.

Drug Targeting IGLV1-41

The high expression of IGLV1-41 in various diseases makes it an attractive drug target. Drugs that can specifically target IGLV1-41 and reduce its expression have the potential to treat these diseases. One approach to drug targeting IGLV1-41 is to use small molecules that can inhibit its expression or activity. For example, inhibitors of the IGLV1-41 gene have been shown to be effective in reducing the expression of IGLV1-41 in various tissues and cells.

Another approach to drug targeting IGLV1-41 is to use antibodies that can specifically recognize and target IGLV1-41. These antibodies have been shown to be effective in reducing the expression and activity of IGLV1-41 in various tissues and cells. The use of antibodies against IGLV1-41 has the potential to treat

Protein Name: Immunoglobulin Lambda Variable 1-41 (pseudogene)

The "IGLV1-41 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV1-41 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets